Variable | Group 2 | Controls | ||
---|---|---|---|---|
before lockdown | after lockdown | visit 1 | visit 2 | |
Population number | 12 | 12 | 11 | 11 |
Chronological age at diagnosis (yr) | 7.47 ± 0.53 | – | 7.41 ± 0.61 | – |
Chronological age at follow-up (yr) | 7.95 ± 0.49 | 8.26 ± 0.47 | 7.93 ± 0.51 | 8.31 ± 0.53 |
Time between the two visits (yr) | – | 0.31 ± 0.02 | – | 0.38 ± 0.02 |
Height, SDS | 0.87 ± 1.22 | 0.89 ± 1.25 | 0.86 ± 1.13 | 0.90 ± 1.16 |
BMI, SDS | 0.61 ± 0.85 | 0.92 ± 0.87 | 0.60 ± 0.93 | 0.69 ± 0.94 |
Δ BMI, SDS | – | 0.32 ± 0.02*** | – | 0.09 ± 0.01*** |
Tanner stage, percentage | ||||
 II | 47.6 | -*** | 63.6 | 54.5 |
 III | 52.4 | 71.4*** | 36.4 | 45.5 |
 IV | – | 28.6*** | – | – |
 V | – | – | – | – |
Basal LH (IU/L) | 0.8 ± 0.6* | 1.4 ± 0.6* | 0.9 ± 0.7 | 1.1 ± 0.7 |
Basal FHS (IU/L) | 1.9 ± 1.5 | 1.5 ± 1.3 | 1.6 ± 1.4 | 1.5 ± 1.2 |
Peak LH at GnRH stimulation (IU/L) | 9.6 ± 3.4* | 12.5 ± 3.1* | 9.0 ± 3.1 | 11.7 ± 3.3 |
Basal estradiol (females only) | 111.3 ± 15.2** | 133.4 ± 18.3** | 113.8 ± 13.9 | 119.1 ± 15.4 |
Uterine length, cm | 4.10 ± 0.49* | 4.59 ± 0.47* | 4.00 ± 0.35 | 4.35 ± 0.37 |
Ovarian volume, cm3 | 2.94 ± 0.52* | 3.43 ± 0.48* | 2.86 ± 0.46 | 3.18 ± 0.46 |
Electronic device use (h) | 1.6 ± 0.9*** | 3.9 ± 1.5*** | – | – |